95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Breast Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1527277
This article is part of the Research Topic Evidence-Based Research and Clinical Application of Adverse Reactions and Management Strategies for Cancer Treatment Drugs View all articles
Efficacy and safety of pyrotinib in the treatment of HER2-positive liver metastatic advanced breast cancer
Provisionally accepted
Yongxia Li 1 Yong Li 2 Taolang Li 3 Mingyuan He 1 Jianying Chang 1 Hui Cao 2 Daiqin Luo 1 Junyuan Lv 3 Yunbi Zou 4 Yuyan Zheng 4
Li Ran 5,6* Feiyue Yang 2* Li Huang 4* Xiaoming Chen 3*- 1 Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou Province, China
- 2 Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, China
- 3 Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China
- 4 Hospital of Guizhou Panjiang Coal Power Group Co., LTD., Guizhou, China
- 5 Guizhou Medical University, Guiyang, Guizhou Province, China
- 6 The affiliated cancer hospital of Guizhou medical university, Guizhou, China
Background: This study aimed to evaluate the efficacy and safety of pyrotinib in the treatment of HER2-positive breast cancer patients with and without liver metastasis.A retrospective analysis was conducted on 91 patients with HER2-positive advanced breast cancer, who were treated with pyrotinib between March 2019 and April 2022. The patients were categorized into two groups based on the presence or absence of liver metastases, and their overall survival (OS), progression-free survival (PFS), and their response to pyrotinib were compared. Adverse effects in the patients were analyzed to assess the safety of pyrotinib.The cohort include 29 patients with liver metastasis and 62 without. The median overall survival was significantly shorter in the liver metastasis group (15.8 months) than that in the non-liver metastasis group (31.4 months, P = 0.0036). A statistically significant difference was observed in the median PFS between the liver metastasis and the non-liver metastasis groups (8.7 vs. 18.4 months) (P = 0.0272). Univariate analysis revealed that patients with younger age (<60 years) (P < 0.0001), negative progesterone receptor expression (P = 0.0028), higher Ki67 expression levels (P < 0.0001), and absence of lymph node metastasis (P < 0.0001) were more likely to benefit from pyrotinib treatment. Comparative analysis between groups showed significantly higher incidence rates of anemia (58.6% vs. 40.3%) and elevated aspartate transaminase level (31.0% vs 8.1%) in the liver metastasis group compared to the non-liver metastasis (P < 0.05).
Keywords: breast cancer, Pyrotinib, HER2-positive, liver metastasis, efficacy and safety
Received: 13 Nov 2024; Accepted: 24 Mar 2025.
Copyright: © 2025 Li, Li, Li, He, Chang, Cao, Luo, Lv, Zou, Zheng, Ran, Yang, Huang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Li Ran, Guizhou Medical University, Guiyang, 550025, Guizhou Province, China
Feiyue Yang, Guizhou Provincial People's Hospital, Guiyang, Guizhou Province, China
Li Huang, Hospital of Guizhou Panjiang Coal Power Group Co., LTD., Guizhou, China
Xiaoming Chen, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, Guizhou Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.